Tetravalent SARS-CoV-2 Neutralizing Antibodies Show Enhanced Potency and Resistance to Escape Mutations.

doi:10.1016/j.jmb.2021.167177

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Tetravalent SARS-CoV-2 Neutralizing Antibodies Show Enhanced Potency and Resistance to Escape Mutations.

Journal of molecular biology - 17 Sept 2021

Miersch Shane, Li Zhijie, Saberianfar Reza, Ustav Mart, Brett Case James, Blazer Levi, Chen Chao, Ye Wei, Pavlenco Alevtina, Gorelik Maryna, Garcia Perez Julia, Subramania Suryasree, Singh Serena, Ploder Lynda, Ganaie Safder, Chen Rita E, Leung Daisy W, Pandolfi Pier Paolo, Novelli Giuseppe, Matusali Giulia, Colavita Francesca, Capobianchi Maria R, Jain Suresh, Gupta J B, Amarasinghe Gaya K, Diamond Michael S, Rini James, Sidhu Sachdev S

Abstract excerpt

Neutralizing antibodies (nAbs) hold promise as therapeutics against COVID-19. Here, we describe protein engineering and modular design principles that have led to the development of synthetic bivalent and tetravalent nAbs against SARS-CoV-2. The best nAb targets the host receptor binding site of the viral S-protein and tetravalent versions block entry with a potency exceeding bivalent nAbs by an order of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Angiotensin-Converting Enzyme 2

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antibodies, Neutralizing

Share to Antibodies, Viral

Share to COVID-19 Drug Treatment

Share to Immunoglobulin G

Share to Protein Engineering

Share to Spike Glycoprotein, Coronavirus

Share to Vero Cells

Source

Open in PubMed Open full text

Identifiers

PMID: 34329642
DOI: 10.1016/j.jmb.2021.167177
PMCID: PMC8316672

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Tetravalent SARS-CoV-2 Neutralizing Antibodies Show Enhanced Potency and Resistance to Escape Mutations.PMID 34329642Read ↗

Peptide-antibody Fusions Engineered by Phage Display Exhibit Ultrapotent and Broad Neutralization of SARS-CoV-2 VariantsSemantic proximity Read ↗

Broad‐Spectrum Engineered Multivalent Nanobodies Against SARS‐CoV‐1/2Semantic proximity Read ↗

Broad Neutralizing Antibodies Against SARS-CoV-2: Current Progress and Engineering Strategies.Semantic proximity Read ↗

Versatile, Multivalent Nanobody Cocktails Efficiently Neutralize SARS-CoV-2Semantic proximity Read ↗

Arsenal of nanobodies shows broad-spectrum neutralization against SARS-CoV-2 variants of concern in vitro and in vivo in hamster modelsSemantic proximity Read ↗

Biparatopic sybody constructs neutralize SARS-CoV-2 variants of concern and mitigate emergence of drug resistanceSemantic proximity Read ↗

Application of a Method for Engineering Multivalent Antibodies to Substantially Enhance Functional affinity of Clinical Trial Anti-SARS-CoV-2 AntibodiesSemantic proximity Read ↗

Biparatopic sybodies neutralize SARS‐CoV‐2 variants of concern and mitigate drug resistanceSemantic proximity Read ↗

Development of a bispecific nanobody conjugate broadly neutralizes diverse SARS-CoV-2 variants and structural basis for its broad neutralizationSemantic proximity Read ↗

An ultrapotent RBD-targeted biparatopic nanobody neutralizes broad SARS-CoV-2 variantsSemantic proximity Read ↗

Dual Epitope Engagement Enables Broad-Spectrum Neutralization of SARS-CoV-2 Variants by Bispecific Antibody 9A6-6C3Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.